Date: 2015-10-13
Type of information: Commercialisation agreement
Compound: 89Zr-Df-IAB2M
Company: ImaginAb (USA - CA) JFE Engineering (Japan)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: commercialisation distribution
Action mechanism: Imaging agent/radiopharmaceutical. 89Zr-Df-IAB2M is a radio-labelled antibody fragment (a “Minibody”) under clinical development as a diagnostic imaging agent for use with positron emission tomography/computed tomography (PET/CT) for detection of soft tissue and bone lesions in metastatic prostate cancer. 89Zr-Df-IAB2M targets prostate-specific membrane antigen (PSMA), a transmembrane protein highly expressed in the majority of prostate cancer, both localized and metastatic disease. PSMA has also been shown to be significantly overexpressed in response to androgen depletion, potentially enabling it to be used as a marker of response to anti-androgen therapy in patients with castrate-resistant disease. IAB2M is a hepatically-cleared imaging agent, meaning that there is no renal clearance and no bladder signal to obfuscate small lesions in the prostate bed. Ongoing clinical studies are evaluating the safety of the 89Zr-Df-IAB2M tracer and its ability to accurately determine the extent of disease in several distinct prostate cancer patient populations with unmet clinical need.
Disease: detection of soft tissue and bone lesions in men with high risk prostate cancer
Details: * On February 23, 2015, ImaginAb and JFE Engineering have concluded an MOU to conduct market and distribution feasibility for ImaginAb’s product portfolio in the Japanese market, with an initial focus on ImaginAb’s product for imaging urologic malignancies (89Zr-Df-IAB2M) currently in Phase II development. 89Zr-Df-IAB2M is ImaginAb’s lead drug candidate, under development as a diagnostic imaging agent for use with positron emission tomography/computed tomography (PET/CT) for detection of soft tissue and bone lesions in men with high risk prostate cancer.
Financial terms:
Latest news:
